GPX3 and urinary bladder carcinoma: Recently, downregulation of GPX3 by promoter hypermethylation has been reported in multiple human cancers, such as prostate, gastric, esophageal, cervical, and bladder cancer [15,16,17], suggesting that GPX3 serves as a tumor suppressor in these cancers.